Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
39.45(c) 39.35(c) 38.2(c) 37.5(c) 39.2(c) Last
116 374 80 978 61 017 52 149 121 861 Volume
+2.73% -0.25% -2.92% -1.83% +4.53% Change
More quotes
Financials ( CHF)
Sales 2017 23,0 M
EBIT 2017 -35,5 M
Net income 2017 -36,0 M
Finance 2017 17,0 M
Yield 2017 -
Sales 2018 45,4 M
EBIT 2018 -14,0 M
Net income 2018 -19,0 M
Finance 2018 7,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 9,51x
EV / Sales2018 5,04x
Capitalization 236 M
More Financials
Company
Santhera Pharmaceuticals Holding AG is a pharmaceutical company, which focuses on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.It offers treatments under the Raxone and Catena brands.The company was founded on... 
Sector
Pharmaceuticals
Calendar
02/21Presentation
More about the company
Surperformance© ratings of Santhera Pharmaceuticals H
Trading Rating : - Investor Rating :
More Ratings
Latest news on SANTHERA PHARMACEUTICALS H
07:01a SANTHERA PHARMACEUTICALS : Plans to Announce Regulatory Feedback for Raxone® in ..
2017 SANTHERA PHARMACEUTICALS : Launches 'Take a Breath DMD' Respiratory Disease Awar..
2017 SANTHERA PHARMACEUTICALS : Launches "Take a Breath DMD" Respiratory Disease Awar..
2017 SANTHERA PHARMACEUTICALS : Launches “Take a Breath DMD” Respiratory ..
2017 SANTHERA PHARMACEUTICALS : Launches "Take a Breath DMD" Respiratory Disease Awar..
2017 Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and ..
2017 SANTHERA PHARMACEUTICALS : Summit Therapeutics, Catabasis Pharmaceuticals and Du..
2017 SANTHERA PHARMACEUTICALS : Todd Bazemore Steps Down from Role as Chief Operating..
2017 SANTHERA PHARMACEUTICALS : Todd Bazemore Steps Down from Role as Chief Operating..
2017 SANTHERA PHARMACEUTICALS : Todd Bazemore Steps Down from Role as Chief Operating..
More news
Sector news : Specialty & Advanced Pharmaceuticals
11:16a SHIRE PLC SHIRE PLC : Directorate Change
01:20a At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
01/18 ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
01/18 BTG : U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's ..
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
07:01aSanthera Pharmaceuticals : Plans to Announce Regulatory Feedback for Raxone® .. 
2017'Quality, access and affordablity.' Watch Thomas Meier accept our Deal of the.. 
2017Thomas Meier accepts our Deal of the Year award last night for Kaiser Permane.. 
2017Santhera Pharmaceuticals $SANN.sw, Summit Therapeutics, Catabasis Pharmaceuti.. 
2017Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and .. 
More tweets
Qtime:22
News from SeekingAlpha
2017 Interview - Santhera Readies Muscular Dystrophy Push
2016 Duchenne Assets Soar In The Wake Of Exondys 51 Approval
2016 Recent Setbacks Have Duchenne Investors On Edge
2015 FDA grants Marathon Pharma's DMD candidate deflazacort rare pediatric disease..
2015 Tarix Orphan's TXA127 Fast Track'd for DMD
Chart SANTHERA PHARMACEUTICALS H
Duration : Period :
Santhera Pharmaceuticals H Technical Analysis Chart | SANN | CH0027148649 | 4-Traders
Technical analysis trends SANTHERA PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 49,5  CHF
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Thomas Meier Chief Executive Officer & Director
Elmar J. Schnee Chairman
Christoph Rentsch Chief Financial Officer
Kristina Sjöblom Nygren Chief Medical Officer & Head-Development
Martin Gertsch Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
SANTHERA PHARMACEUTICALS HOLDING AG4.31%246
ABBVIE5.98%165 483
MERCK KGAA1.86%14 280
KYOWA HAKKO KIRIN CO LTD-2.97%11 212
JAZZ PHARMACEUTICALS PLC11.25%8 948
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.67%6 962